Search clinical trials for: CNTO 1959

Total 237 results

Janssen Inc.

Completed

A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis (X-PLORE)

Psoriasis

United States, Poland, Canada, Belgium, Germany
Centocor, Inc.

Completed

A Study of the Safety and How the Body Affects a Drug (CNTO 1959) in Healthy Volunteers and in Patients With Psoriasis

Psoriasis

United States
Janssen Research & Development, LLC

Completed

A Study of Subcutaneously-administered Guselkumab Delivered by 3 Different Devices in Healthy Participants

Healthy

United States, Germany
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety Study of CNTO1959 (Guselkumab) in the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Pustular Psoriasis

Japan
Janssen Research & Development, LLC

Active, not recruiting

A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis (THEIA)

Giant Cell Arteritis

United States, Canada, Belgium, Israel, Italy, Germany, France, Spain, Poland
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety of CNTO 1959 (Guselkumab) in Participants With Moderate to Severe Plaque-type Psoriasis

Psoriasis

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody in Participants With Palmoplantar Pustulosis

Palmoplantaris Pustulosis

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of the Safety, Tolerability, Pharmacokinetics (What the Body Does to the Drug), and Pharmacodynamics (What the Drug Does to the Body) of CNTO 1959 Following a Single Subcutaneous (Under the Skin) Administration in Japanese Participants With Moderate to Severe Plaque Psoriasis

Psoriasis

Japan
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety of Guselkumab in Participants With Palmoplantar Pustulosis

Palmoplantar Pustulosis

Japan
Janssen Research & Development, LLC

Completed

A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy

Arthritis, Rheumatoid

Poland, Ukraine, Colombia, Bulgaria, United States, Singapore, Russian Federation, Argentina, Hungary, Chile, Czech Republic
Janssen Research & Development, LLC

Completed

A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis (VOYAGE 1)

Psoriasis

United States, Australia, Taiwan, Germany, Spain, Korea, Republic of, Canada, Russian Federation, Poland, Hungary
Janssen Pharmaceutica N.V., Belgium

Completed

A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) Therapy (COSMOS)

Arthritis, Psoriatic

Belgium, France, Israel, Italy, Germany, Bulgaria, Spain, Poland, Russian Federation, United Kingdom, Ukraine, Hungary, Portugal, Greece
Janssen Research & Development, LLC

Completed

Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis

Psoriasis

United States, Canada, Poland
Janssen Research & Development, LLC

Completed

A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab (NAVIGATE)

Psoriasis

United States, Poland, United Kingdom, Germany, Taiwan, Spain, Australia, Canada, Korea, Republic of, Russian Federation
Janssen Research & Development, LLC

Recruiting

A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX)

Arthritis, Psoriatic

Israel, United States, Germany, Taiwan, Korea, Republic of, Malaysia, China, Georgia, Poland, Spain, Philippines, Hungary, Italy, Canada, Bulgaria, Russian Federation, Serbia, Slovenia, Bosnia and Herzegovina, Greece, Ukraine, Cze... and more
Janssen Research & Development, LLC

Completed

A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis

Arthritis, Psoriatic

United States, Turkey, Malaysia, Czechia, Bulgaria, Poland, Russian Federation, Ukraine, Spain, Taiwan, Latvia, Estonia, Lithuania
Janssen Research & Development, LLC

Completed

A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s) (Discover-1)

Arthritis, Psoriatic

United States, Canada, Taiwan, Hungary, Malaysia, Germany, Czechia, Korea, Republic of, Russian Federation, Spain, Australia, Ukraine, Poland
Institute for Molecular Medicine
National Institute on Aging (NIA); Clinartis

Recruiting

Study of AV-1959, an Amyloid Beta Vaccine

Alzheimer Disease

United States
Janssen Research & Development, LLC

Completed

A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment (VOYAGE 2)

Psoriasis

United States, Australia, Poland, Germany, Spain, Korea, Republic of, Canada, Russian Federation, Czechia
Norwegian Center for Violence and Traumatic Stress...

Completed

Implementation of Truma-Focused Cognitive Behavioral Therapy (TF-CBT) in Norway (TF-CBT)

PTSD
University of Liege

Recruiting

Mental Imagery and Psychological Well-being

Depression | Anhedonia

Belgium
Peking Union Medical College Hospital
Zhitong Biopharma CO.,LTD

Unknown

A Study to Evaluate the Efficacy and Safety of Brain Polypeptide Solution in Mild Alzheimer's Disease

Alzheimer Disease
Icahn School of Medicine at Mount Sinai
Gilead Sciences

Completed

Outcomes in Liver Disease Patient With and Without HIV Co-infection-Sub Study 2: HCV Treatment: Health Related Quality

Hepatitis C Infection

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS) (NOVA)

Hidradenitis Suppurativa

United States, France, Canada, Germany, Netherlands, Denmark
Janssen Research & Development, LLC

Terminated

A Study of Guselkumab in Participants With Active Lupus Nephritis (ORCHID-LN)

Lupus Nephritis

United States, Taiwan, Mexico, Spain, Russian Federation, Thailand, Poland, Argentina, Ukraine
University of Saskatchewan

Completed

Tiotropium Efficacy Against Allergen Induced Early Asthmatic Responses

Allergic Asthma

Canada
Novo Nordisk A/S

Completed

Comparison of IDegAsp (Inclusive Three Explorative Formulations) With Insulin Degludec and Insulin Aspart Separately Injected in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis (ECLIPSE)

Psoriasis

United States, Germany, France, Hungary, Czechia, Canada, Spain, Australia, Poland
Washington University School of Medicine

Completed

Exome Sequencing for Atypical Femoral Fractures

Osteoporosis | Atypical Femoral Fractures | Bisphosphonate Therapy
Janssen Research & Development, LLC

Completed

Study of Guselkumab and Ustekinumab Following a Single Intravenous or Subcutaneous Administration in Healthy Chinese Participants

Healthy

China
Novo Nordisk A/S

Completed

A Research Study to Look at How Insulin Icodec and Semaglutide Work in the Body of People From China With Type 2 Diabetes When Given Alone or Together

Diabetes Mellitus, Type 2

China
Janssen Research & Development, LLC

Completed

Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis

Psoriasis

United States
Amgen

Active, not recruiting

A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201) (FORTITUDE-201)

Squamous-Cell Non-Small-Cell Lung Cancer

France, Belgium, Spain, United States, Taiwan, Korea, Republic of, Japan, Poland
Jonsson Comprehensive Cancer Center

Completed

Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer

Gastric Cancer | Esophageal Cancer

United States
AstraZeneca

Completed

Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United States
National Institute of Allergy and Infectious Diseases...
Eli Lilly and Company; National Heart, Lung, and Blood Institute (NHLBI); University... and other collaborators

Completed

LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

COVID-19

United States, Denmark, Singapore, Spain
Janssen-Cilag Ltd.

Recruiting

Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients (REASON)

Crohn's Disease

Taiwan, Israel
Montefiore Medical Center
Icahn School of Medicine at Mount Sinai; Janssen Scientific Affairs, LLC

Recruiting

Social Determinants of Health, Medication Use, and Quality of Life in Inflammatory Bowel Disease

Inflammatory Bowel Diseases

United States
Janssen Research & Development, LLC

Recruiting

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (QUASAR Jr)

Colitis, Ulcerative

Belgium, United States, China, Denmark, Spain, Japan, Italy, Turkey, Poland, France, Portugal
SWOG Cancer Research Network
National Cancer Institute (NCI)

Not yet recruiting

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Lung Non-Small Cell Carcinoma
Janssen Research & Development, LLC

Recruiting

Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM)

Moderate Plaque Psoriasis

United States, Canada
University of Washington
Janssen Scientific Affairs, LLC

Recruiting

Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study

Castration-Resistant Prostate Carcinoma | Prostate Adenocarcinoma

United States
Janssen Research & Development, LLC

Recruiting

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease (MACARONI-23)

Crohn's Disease

Poland, United States, Japan, Spain, Norway
University of Pennsylvania
Janssen Scientific Affairs, LLC

Recruiting

Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients (EVOLUTION)

Psoriatic Arthritis

United States
Janssen-Cilag Ltd.

Recruiting

A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease (FUZION CD)

Fistulizing Crohns Disease | Perianal Crohns Disease

Netherlands, United States, Belgium, Korea, Republic of, Taiwan, Israel, Japan, Canada, Hungary, Germany, Greece, United Kingdom, Australia, Spain, Saudi Arabia, Poland, Turkey, Portugal, Czechia, Italy, Jordan, France
Janssen Research & Development, LLC

Recruiting

A Long-term Extension Study of Ustekinumab in Pediatric Participants (UNITED)

Crohn Disease | Arthritis, Psoriatic | Colitis, Ulcerative

Belgium, France, United States, Hungary, Japan, United Kingdom, Germany, Poland, Argentina
Janssen Research & Development, LLC

Recruiting

A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis (PSUMMIT-Jr)

Arthritis, Juvenile

United States, France, United Kingdom, Turkey, Spain, Argentina, Germany, Italy, Poland, Denmark
GI Alliance
Mayo Clinic; University of Wisconsin, Madison; Janssen, LP

Not yet recruiting

Sustained Humoral and Cell-Mediated Immunogenicity of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease

Inflammatory Bowel Diseases

United States
Janssen Research & Development, LLC

Recruiting

Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent (SOLSTICE)

Arthritis, Psoriatic

Israel, Turkey, United States, Hungary, Spain, Australia, Bulgaria, Czechia, Malaysia, Poland, Puerto Rico, Russian Federation, Ukraine, Argentina
Janssen Research & Development, LLC

Recruiting

A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease (STAR)

Arthritis, Psoriatic

Italy, Germany, Taiwan, United States, Malaysia, Turkey, Georgia, Canada, Hong Kong, Portugal, Denmark, Israel, Philippines, Thailand, Bulgaria, Australia, Czechia, Hungary, Poland, Russian Federation, Ukraine, Spain, Argentina, United... and more

Search clinical trials for: CNTO 1959

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tanzania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations